E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Amyotrophic lateral sclerosis (ALS) |
|
E.1.1.1 | Medical condition in easily understood language |
ALS is a disorder that affects the function of nerves and muscles,eventually taking away the ability to walk, dress, write, speak, swallow, and breathe and shortening the life span. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002026 |
E.1.2 | Term | Amyotrophic lateral sclerosis |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to confirm that levosimendan can significantly improve respiratory function measured by supine slow vital capacity (SVC) in amyotrophic lateral sclerosis (ALS) patients. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to confirm that levosimendan improves the functionality of subjects, measured by Revised ALS Functional Rating Scale (ALSFRS-R), Clinical Global Impression (CGI), Borg Category Ratio 10
(CR10) scale on dyspnea (shortness of breath), Epworth Sleepiness scale (ESS) and Pittsburgh Sleep Quality Index (PSQI). The latter two are sleep scales assessing daytime somnolence and sleep quality, respectively.
In addition, the long-term tolerability and safety of levosimendan in ALS patients will be evaluated, assessing up to 48 weeks of exposure. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Optional Future Genetic Research, as part of the main protocol. The DNA of subjects who have given a separate Pharmacogenetic Informed Consent will be stored to allow possible exploratory PG research to assess whether genetic polymorphisms relate to the absorption, distribution, metabolism, excretion, pharmacodynamics or safety of levosimendan. |
|
E.3 | Principal inclusion criteria |
1. Written or verbal informed consent (IC) for participation in the study will be obtained from the subject. In case that the study subject him/herself cannot sign the IC due to severe muscle weakness, a witness may sign the consent form to indicate that the subject has given verbal consent.
2. Age at least 18 years.
3. Male or female subjects with diagnosis of laboratory supported probable, probable or definite ALS according to El Escorial revised criteria (Brooks BR et al., 2000). Full electromyogram (EMG) report available consistent with ALS (but not necessarily fulfilling the electrodiagnostic criteria for ALS) from an experienced neurophysiologist.
4. Able to swallow study treatment capsules, and in the opinion of the investigator, is expected to continue to do so during the study.
5. Sitting SVC between 60-90% of the predicted value for age, height and sex at screening visit.
6. Disease duration from symptom onset (defined by first muscle weakness or dysarthria) 12- 48 months at the time of visit 1 (baseline).
7. Able to perform supine SVC in an adequate and reliable way at screening and baseline visits as judged by the investigator.
8. Subjects with or without riluzole and/or edaravone. If using riluzole (any daily dose up to 100 mg), the dose must have been stable for at least 4 weeks before the screening visit and should not be changed during the study. If using edaravone, the treatment should have been started at least 4 weeks before the screening visit (at least one 28-day treatment cycle as indicated) and should not be changed during the study. If not on riluzole and/or edaravone, the respective treatments should not be started during the study. |
|
E.4 | Principal exclusion criteria |
1. Subject in whom other causes of neuromuscular weakness have not been excluded.
2. Subject with a diagnosis of another neurodegenerative disease (e.g. Parkinson’s or Alzheimer’s disease).
3. Assisted ventilation of any type within 3 months before the screening visit or at screening.
4. Any use of a diaphragm pacing system (DPS) within 3 months before the screening visit.
5. Any form of stem cell or gene therapy for the treatment of ALS.
6. Known hypersensitivity to levosimendan.
7. Administration of levosimendan within 3 months before the screening visit or previous participation in the present phase III study or earlier study with oral levosimendan in ALS patients (LEVALS).
8. Any use of tirasemtiv or reldesemtiv within 1 month before the screening visit.
9. Participation in a clinical trial with any experimental treatment within 30 days or within 5 half-lives of that treatment (whichever is longer) before the screening visit.
10. Any botulinum toxin use within 3 months before the screening visit.
11. Recorded diagnosis or evidence of major psychiatric diagnosis, significant cognitive impairment or clinically evident dementia that may interfere with the patient’s ability to comply with study procedures.
12. Pulmonary illness (e.g. asthma or COPD) requiring regular treatment.
13. Haemodynamically significant uncorrected valve disease or hypertrophic cardiomyopathy or restrictive cardiomyopathy.
14. Any cardiovascular event (e.g. myocardial infarction, HF, arrhythmia or stroke) requiring hospitalisation within 3 months before the screening visit.
15. History of Torsades de Pointes (TdP) or diagnosed long QT-syndrome.
16. History of life-threatening ventricular arrhythmia, unless treated with reliable measures to prevent recurrence (e.g. with placement of implantable cardioverter defibrillator [ICD] or catheter ablation).
17. History of second or third degree atrioventricular (AV) block or sinus node disease at screening, if not treated with pacemaker.
18. HR repeatedly > 100 bpm in the 12-lead ECG after a 5-minute rest at screening. If the HR is > 100 bpm in the first recording, then the second recording must be done after another 5 min rest to confirm HR > 100 bpm.
19. Systolic blood pressure (SBP) < 90 mmHg at screening.
20. Potassium < 3.7 mmol/l or > 5.5 mmol/l at screening.
21. Severe renal impairment (creatinine clearance < 30 ml/min at screening), creatinine > 170 μmol/l at screening or on dialysis.170 μmol/l at screening or on dialysis.
22. Blood haemoglobin < 10 g/dl at screening or blood donation or loss of significant amount of blood within 60 days before the screening visit.
23. Clinically significant hepatic impairment at the discretion of the investigator.
24. Body mass index (BMI) ≤ 18.5kg/m2 (BMI = weight/height2).
25. Women who are lactating or of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of contraception (e.g. oral hormonal contraceptives associated with inhibition of ovulation, intrauterine devices and long acting progestin agents), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included.
26. Patient judged to be actively suicidal by the investigator during 3 months before the screening visit.
27. Patients with known history of human immunodeficiency virus (HIV) infection.
28. Any other clinically significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary efficacy variable SVC % measured in supine position. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary evaluation will be performed at 12 weeks and contrasts will be used to obtain estimates for each of the visit from the primary model including all SVC measurements prior to 12 weeks. Additional evaluations will be performed including all data through 48 weeks. |
|
E.5.2 | Secondary end point(s) |
Secondary efficacy endpoints will be tested in following hierarchy to preserve the overall alpha level:
1. Combined assessment of ALSFRS-R function and survival through 48 weeks
2. Time to respiratory event trough 48 weeks
3. CGI through 48 weeks
4. Supine Borg CR 10 scale at 12 weeks
5. Slope of decline in respiratory function of ALSFRS-R through 48 weeks
The efficacy variables time to respiratory event, time to NIV or death, time to SVC (supine) decline of 20%, time to SVC (supine) ≤ 50% of predicted, time to ALSFRS-R total score decline of 20% and time to decline in ALSFRS-R respiratory domain will be evaluated. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The total duration for double-blind comparison will be 48 weeks. Interim/futility analyses will be done when approximately 50% and 100% of the subjects have been treated for 12 weeks. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 43 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Belgium |
Canada |
Finland |
France |
Germany |
Ireland |
Italy |
Netherlands |
Spain |
Sweden |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS (Last visit last subject) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |